| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 02/23/1999 | US5874447 High purity organosulfonate salt of paroxetine with excellent stability, solubility; react with a base to make high purity paroxetine, or with a reagent to make the high purity salt of said reagent (ex: paroxetine maleate from maleic acid) |
| 02/23/1999 | US5874428 N-substituted aza-heterocyclic carboxylic acids and esters thereof |
| 02/23/1999 | US5874426 Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists |
| 02/23/1999 | US5874252 Splicing variant of the Epstein-Barr virus-induced G-protein coupled receptor |
| 02/23/1999 | US5874245 Human G-protein coupled receptor (HIBCD07) |
| 02/23/1999 | US5874086 Synthetic polypeptide analogs of parathyroid hormone (pth), parathyroid hormone related peptide (pthrp), and of the physiologically active truncated homologs and analogs of pth and pthrp; forming an amphipathic alpha-helix |
| 02/20/1999 | CA2241429A1 Cxcr4b: a human splice variant of cxcr4 chemokine receptor |
| 02/18/1999 | WO1999007737A2 Lsr receptor, cloning and uses |
| 02/18/1999 | WO1999007736A2 Lipoprotein-regulating medicaments |
| 02/18/1999 | WO1999007729A2 Peptides having potassium channel opener activity |
| 02/18/1999 | WO1999007720A2 Process for the purification of acarbose, pharmaceutical composition containing same and its use for the treatment of diabetes |
| 02/18/1999 | WO1999007703A1 4-AMINOPYRROLE(3,2-d) PYRIMIDINES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS |
| 02/18/1999 | WO1999007404A1 Novel exendin agonist compounds |
| 02/18/1999 | WO1999007398A1 Products from cypress and all relative coniferous trees and their pharmaceutical uses |
| 02/18/1999 | WO1999007387A1 Chromium/biotin treatment of type ii diabetes |
| 02/18/1999 | WO1999007362A1 A PROCESS FOR STABIlIZING LEVOGYRE ASCORBIC ACID (LAA) AND STABLE LAA COMPOSITIONS |
| 02/18/1999 | WO1999007352A2 Method for promoting expression of ldl receptor gene |
| 02/18/1999 | WO1999007224A1 Compositions and methods for treating diabetes |
| 02/18/1999 | WO1998051348A3 Sustained-release delayed gels |
| 02/18/1999 | WO1998036764A3 Method of treating psychological and metabolic disorders using igf or igf/igfbp-3 |
| 02/18/1999 | CA2301669A1 Peptides having potassium channel opener activity |
| 02/18/1999 | CA2299425A1 Novel exendin agonist compounds |
| 02/18/1999 | CA2298849A1 Lipoprotein-regulating medicaments |
| 02/18/1999 | CA2274302A1 Lsr receptor, activity, cloning, and uses for diagnosing, preventing and/or treating obesity and related risks or complications |
| 02/18/1999 | CA2268030A1 A process for stabilizing levogyre ascorbic acid (laa) and stable laa compositions |
| 02/18/1999 | CA2245041A1 Optical active 1,4-dihydropyridine compounds as bradykinin antagonists |
| 02/17/1999 | EP0896822A1 4-Aminopyrrole (3,2-d) pyrimidines as neuropeptide Y receptor antagonists |
| 02/17/1999 | EP0896538A1 Use of dipeptidyl peptidase iv inhibitors for lowering the blood glucose level in mammals |
| 02/17/1999 | EP0896533A2 Pentafluorobenzenesulfonamides and analogs |
| 02/17/1999 | EP0896516A1 Diabetic supplement bar |
| 02/17/1999 | CN1208420A Antisecretory factor peptides regulating pathological permeability changes |
| 02/17/1999 | CN1208418A Pyrido-1,2,4-thiadiazine and pyrido-1,4-thiazine derivatives, their preparation and use |
| 02/17/1999 | CN1208417A Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use |
| 02/17/1999 | CN1208034A Crystal form of N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide |
| 02/16/1999 | US5872149 Alk(en)yldicarboxylic acid bisesters, their use, and processes for their preparation |
| 02/16/1999 | US5872130 Quinoline type mevalonoactones |
| 02/16/1999 | US5872094 Method for attaching cartilaginous tissue, cartilage matrix protein or link protein to a surface |
| 02/16/1999 | US5871799 Foods and beverages having decreased digestive and absorptive properties |
| 02/15/1999 | CA2224096A1 The g-protein coupled receptor hfia041 |
| 02/11/1999 | WO1999006558A1 Human longevity-assurance protein homologs |
| 02/11/1999 | WO1999006434A1 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 02/11/1999 | WO1999006433A1 Compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 02/11/1999 | WO1999006432A1 Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 02/11/1999 | WO1999006426A1 Novel molecules of the tango-77 related protein family and uses thereof |
| 02/11/1999 | WO1999006423A1 83 human secreted proteins |
| 02/11/1999 | WO1999006421A1 Synthetic insulin mimetic substances |
| 02/11/1999 | WO1999006395A1 Pyridyl- and pyrimidyl-heterocyclic compounds inhibiting oxido squalene-cyclase |
| 02/11/1999 | WO1999006391A1 Alpha-9 integrin antagonists and anti-inflammatory compositions therof |
| 02/11/1999 | WO1999006390A1 Carbamyloxy compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 02/11/1999 | WO1999006053A1 N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators |
| 02/11/1999 | WO1999006051A1 Pharmaceutical compositions containing vitamin d and calcium, their preparation and therapeutic use |
| 02/11/1999 | WO1999006039A1 Composition comprising l-carnitine or an alkanoyl l-carnitine and long-chain alkanols |
| 02/11/1999 | WO1999006035A2 COMBINATIONS OF HMG-CoA REDUCTASE INHIBITORS AND NICOTINIC ACID COMPOUNDS AND METHODS FOR TREATING HYPERLIPIDEMIA ONCE A DAY AT NIGHT |
| 02/11/1999 | WO1999006029A1 Ascorbic acid-based formulation with improved colour stability |
| 02/11/1999 | CA2299055A1 Novel molecules of the tango-77 related protein family and uses thereof |
| 02/11/1999 | CA2298852A1 83 human secreted proteins |
| 02/11/1999 | CA2298766A1 Human longevity-assurance protein homologs |
| 02/11/1999 | CA2298624A1 Ascorbic acid-based formulation having improved colour stability |
| 02/11/1999 | CA2297755A1 Synthetic insulin mimetic substances |
| 02/11/1999 | CA2296485A1 N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators |
| 02/11/1999 | CA2290750A1 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 02/11/1999 | CA2290749A1 Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 02/11/1999 | CA2290746A1 Compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 02/10/1999 | EP0896003A1 Peptides for reducing or inhibiting bone resorption, angiogenesis and restenosis |
| 02/10/1999 | EP0895479A1 Diabetes treatment |
| 02/10/1999 | EP0710239B1 Novel 9-n-bicyclic nucleoside agents useful as selective inhibitors of proinflammatory cytokines |
| 02/10/1999 | CN1207743A Inhibitors of interleukin-1 'beta' converting enzyme |
| 02/10/1999 | CN1207740A Novel intermediates and their use to prepare N,N'-bridged bisindolylmaleimides |
| 02/10/1999 | CN1207675A Sublingual and buccal administration of selegiline |
| 02/10/1999 | CN1207320A Calcium antagonist having parathyroid hormone secretion inhibition, preparing method and use thereof |
| 02/10/1999 | CN1207317A Fat regulating tablet for treating hyperlipidemia and preparing method thereof |
| 02/10/1999 | CN1207296A Method for preparing pantocrine injection |
| 02/10/1999 | CN1207294A Potassium and magnesium controlled-release tablet and producing method thereof |
| 02/10/1999 | CN1042026C 25 carboxylic deriv. of vitamin D series, its preparing method, middle products in production of same and medicine contg. same and pharmaceutical use of same in treatment |
| 02/09/1999 | US5869638 Bone-related cadherin-like protein and process for its production |
| 02/09/1999 | US5869531 No undesireable salidiuretic properties; treating ischemia induced disorders |
| 02/09/1999 | US5869518 Azacycloalkane derivatives, their preparation and their application in therapy |
| 02/09/1999 | US5869511 Isoxazoline compounds as inhibitors of TNF release |
| 02/09/1999 | US5869495 Treatment and/or prophylaxis of hyperglycaemia |
| 02/09/1999 | US5869492 Condensed thiazole derivatives, having 5-HT receptor affinity |
| 02/09/1999 | US5869485 Treatment of diseases which respond to inhibition of the activity of the protein tyrosine kinase |
| 02/09/1999 | US5869471 Methods for the treatment of arthritis using phosphonates and NSAIDS |
| 02/09/1999 | US5869452 Treatment of obesity |
| 02/09/1999 | US5869444 Osmotic agents for peritoneal dialysis |
| 02/09/1999 | US5869270 Single chain MHC complexes and uses thereof |
| 02/09/1999 | US5869265 Screening modulators by contacting recombinant cells which express cotransporter with substance, determining increase or decrease in activity; anticholesterol agents; antidiabetic agents; liver disease; crohn's disease |
| 02/09/1999 | US5869037 Adenoviral-mediated gene transfer to adipocytes |
| 02/09/1999 | CA2210023C Process for the preparation of paroxetine hydrochloride anhydrate form a. |
| 02/04/1999 | WO1999005527A2 Methods for diagnosis and therapy of autoimmune disease, such as insulin dependent diabetes mellitus, involving retroviral superantigens |
| 02/04/1999 | WO1999005175A2 Diagnosis and treatment of diseases using anti-anti-t-cell receptor vbeta anti-bodies or peptides which are recognized by said antibodies, and endocrine secretion regulatory protein i (esrp1) |
| 02/04/1999 | WO1999005134A1 Substituted 1,2,3,4-tetrahydronaphthalene derivatives |
| 02/04/1999 | WO1999005107A1 Vitronectin receptor antagonist |
| 02/04/1999 | WO1999004804A1 Maternal immune secretions and their use in the treatment and/or prophylaxis of conditions of the human body |
| 02/04/1999 | WO1999004799A1 Fatty emulsions containing reducing sugar and method for sterilizing the same |
| 02/04/1999 | WO1999004782A1 Therapeutic and dietary compositions containing essential fatty acids and bioactive disulphides |
| 02/04/1999 | WO1999004773A2 Method for inhibiting bone resorption |
| 02/04/1999 | DE19733094A1 Formulierung auf der Basis von Ascorbinsäure mit verbesserter Farbstabilität Formulation based on ascorbic acid with improved color stability |
| 02/04/1999 | CA2297910A1 Vitronectin receptor antagonist |
| 02/04/1999 | CA2297491A1 Methods for diagnosis and therapy of autoimmune disease, such as insulin dependent diabetes mellitus, involving retroviral superantigens |
| 02/04/1999 | CA2297183A1 Maternal immune secretions and their use in the treatment and/or prophylaxis of conditions of the human body |